Bartolome R Celli

List of Publications by Year
in descending order

323 papers	40,949 citations	4146 87 h-index	2571 195 g-index
398 all docs	398 docs citations	398 times ranked	22176 citing authors

#	Article	IF	Citations
1	Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD in TIOSPIR and UPLIFT. Annals of the American Thoracic Society, 2022, 19, 204-213.	3.2	18
2	Comorbidities in Patients With Chronic Obstructive Pulmonary Disease. , 2022, , 663-674.		0
3	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Preâ€"Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	5.6	72
4	ANTES: Un aÃ±o despuÃ©s en la EPOC. Archivos De Bronconeumologia, 2022, 58, 291-294.	0.8	1
5	The 7 Cardinal Sins of COPD in Spain. Archivos De Bronconeumologia, 2022, 58, 498-503.	0.8	0
6	Chest <scp>CT</scp>â€assessed comorbidities and allâ€cause mortality risk in <scp>COPD</scp> patients in the <scp>BODE</scp> cohort. Respirology, 2022, 27, 286-293.	2.3	26
7	Blood Eosinophils in Chinese COPD Participants and Response to Treatment with Combination Low-Dose Theophylline and Prednisone: A Post-Hoc Analysis of the TASCS Trial. International Journal of COPD, 2022, Volume 17, 273-282.	2.3	0
8	Reply to Bhatt and Ramakrishnan, et al.. American Journal of Respiratory and Critical Care Medicine, 2022, , .	5.6	0
9	International Differences in the Frequency of Chronic Obstructive Pulmonary Disease Exacerbations Reported in Three Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 25-33.	5.6	11
10	[Translated article] The ANTES Program in COPD: First Year. Archivos De Bronconeumologia, 2022, 58, T291-T294.	0.8	0
11	Selecting the Right Patient: The Achilles Heel of COPD Clinical Trials. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 1051-1052.	5.6	1
12	Muscle loss in <scp>COPD</scp>: An â€˜implodingâ€™ phenotype in need of therapies. Respirology, 2021, 26, 8-9.	2.3	1
13	Pharmacotherapy and Lung Function Decline in Patients with Chronic Obstructive Pulmonary Disease. A Systematic Review. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 689-698.	5.6	42
14	From GOLD 0 to Pre-COPD. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 414-423.	5.6	119
15	The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD: the TASCS randomised controlled trial. European Respiratory Journal, 2021, 57, 2003338.	6.7	24
16	Nocturnal Hypoxemia and CT Determined Pulmonary Artery Enlargement in Smokers. Journal of Clinical Medicine, 2021, 10, 489.	2.4	2
17	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. Archivos De Bronconeumologia, 2021, 57, 36-41.	0.8	9
18	Pharmacotherapy Impacts on COPD Mortality. Archivos De Bronconeumologia, 2021, 57, 5-6.	0.8	4

#	Article	IF	Citations
19	Triple Therapy Is Also Effective in Real-World When Used in Chronic Obstructive Pulmonary Disease Patients Who Are Frequent Exacerbators. Respiration, 2021, 100, 93-95.	2.6	4
20	Improving lung health in low-income and middle-income countries: from challenges to solutions. Lancet, The, 2021, 397, 928-940.	13.7	176
21	Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology, 2021, 26, 532-551.	2.3	67
22	Reply to: Thomson, to Neder et al., and to Wouters. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 112.	5.6	0
23	Challenging the obesity paradox: extreme obesity and COPD mortality in the SUMMIT trial. ERJ Open Research, 2021, 7, 00902-2020.	2.6	15
24	Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respiratory Medicine,the, 2021, 9, 1288-1298.	10.7	75
25	Optimal NIV Medicare Access Promotion: Patients With COPD. Chest, 2021, 160, e389-e397.	0.8	10
26	Spirometry: A practical lifespan predictor of global health and chronic respiratory and non-respiratory diseases. European Journal of Internal Medicine, 2021, 89, 3-9.	2.2	19
27	Executive Summary. Chest, 2021, 160, 1808-1821.	0.8	9
28	Natural Course of the Diffusing Capacity of the Lungs for Carbon Monoxide in COPD. Chest, 2021, 160, 481-490.	0.8	16
29	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. Archivos De Bronconeumologia, 2021, 57, 533-539.	0.8	6
30	Psoas Muscle Density Evaluated by Chest CT and Long-Term Mortality in COPD Patients. Archivos De Bronconeumologia, 2021, 57, 533-539.	0.8	1
31	Metformin: Experimental and Clinical Evidence for a Potential Role in Emphysema Treatment. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 651-666.	5.6	49
32	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1251-1258.	5.6	121
33	Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. Chest, 2021, 160, 872-878.	0.8	22
34	In memorium, Claudio F. Donner, MD (1948â€“2021): respiratory medicine's impresario. Respiratory Medicine, 2021, 188, 106616.	2.9	0
35	Exploring the Impact of Lung Cancer Screening on Lung Cancer Mortality of Smokers With Obstructive Lung Disease: Analysis of the NLST-ACRIN Cohort. Archivos De Bronconeumologia, 2021, 57, 36-41.	0.8	3
36	Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort. European Respiratory Journal, 2021, 57, 2001339.	6.7	26

#	Article	IF	Citations
37	Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies. Lancet Respiratory Medicine,the, 2020, 8, 158-170.	10.7	69
38	Multimorbidity in Patients with Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 405-419.	2.1	38
39	ADAM15 expression is increased in lung CD8+ T cells, macrophages, and bronchial epithelial cells in patients with COPD and is inversely related to airflow obstruction. Respiratory Research, 2020, 21, 188.	3.6	11
40	Methods for a Seamless Transition From Tracheostomy to Spontaneous Breathing in Patients With COVID-19. Respiratory Care, 2020, 65, 1773-1783.	1.6	5
41	Time for a change: anticipating the diagnosis and treatment of COPD. European Respiratory Journal, 2020, 56, 2002104.	6.7	33
42	Long-Term Noninvasive Ventilation in Chronic Stable Hypercapnic Chronic Obstructive Pulmonary Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e74-e87.	5.6	87
43	Sex differences between women and men with COPD: A new analysis of the 3CIA study. Respiratory Medicine, 2020, 171, 106105.	2.9	50
44	Somatotypes trajectories during adulthood and their association with COPD phenotypes. ERJ Open Research, 2020, 6, 00122-2020.	2.6	8
45	A Delphi Consensus Document on the Use of Single-Inhaler Fixed-Dose Triple Therapies in COPD Patients . International Journal of COPD, 2020, Volume 15, 1801-1811.	2.3	2
46	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2015 and GOLD 2019 staging: a pooled analysis of individual patient data. ERJ Open Research, 2020, 6, 00253-2020.	2.6	10
47	Chronic Obstructive Pulmonary Disease in the Twenty-First Century. Clinics in Chest Medicine, 2020, 41, xv-xvii.	2.1	2
48	Machine Learning and Prediction of All-Cause Mortality in COPD. Chest, 2020, 158, 952-964.	0.8	62
49	Smoking Pattern in Men and Women: A Possible Contributor to Sex Differences in Smoke-related Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1048-1051.	5.6	6
50	FEV₁ is a stronger mortality predictor than FVC in patients with moderate COPD and with an increased risk for cardiovascular disease . International Journal of COPD, 2020, Volume 15, 1135-1142.	2.3	35
51	Inhaler device feature preferences among patients with obstructive lung diseases. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Over	1.0	8
52	Report of the Barcelona Boston Lung Conference 2020. Open Respiratory Archives, 2020, 2, 141-142.	0.1	0
53	Metabolic and cardiorespiratory effects of decreasing lung hyperinflation with budesonide/formoterol in COPD: a randomized, double-crossover, placebo-controlled, multicenter trial. Respiratory Research, 2020, 21, 26.	3.6	2
54	Device use errors with soft mist inhalers: A global systematic literature review and meta-analysis. Chronic Respiratory Disease, 2020, 17, 147997311990123.	2.4	23

#	Article	IF	Citations
55	Urgent need of a management plan for survivors of COVID-19. European Respiratory Journal, 2020, 55, 2000764.	6.7	8
56	It is time for the world to take COPD seriously: a statement from the GOLD board of directors. European Respiratory Journal, 2019, 54, 1900914.	6.7	43
57	The most beautiful COPD chart in the world: all together to end COPD!. European Respiratory Journal, 2019, 54, 1902047.	6.7	16
58	Plasma metabolomics and clinical predictors of survival differences in COPD patients. Respiratory Research, 2019, 20, 219.	3.6	22
59	Prognostic Validation Using GesEPOC 2017 Severity Criteria. Archivos De Bronconeumologia, 2019, 55, 409-413.	0.8	4
60	Update on Clinical Aspects of Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2019, 381, 1257-1266.	27.0	264
61	Medication management patterns among Medicare beneficiaries with chronic obstructive pulmonary disease who initiate nebulized arformoterol treatment . International Journal of COPD, 2019, Volume 14, 1019-1031.	2.3	5
62	Itâ€™s more than low BMI: prevalence of cachexia and associated mortality in COPD. Respiratory Research, 2019, 20, 100.	3.6	66
63	Predictors of Nebulized Arformoterol Treatment: A Retrospective Analysis of Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease*. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 140-151.	1.6	2
64	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	27.0	180
65	Enriched Systemic Biomarkers in Symptomatic Unobstructed Smokers. Chest, 2019, 155, 886-887.	0.8	0
66	Serum biomarkers and outcomes in patients with moderate COPD: a substudy of the randomised SUMMIT trial. BMJ Open Respiratory Research, 2019, 6, e000431.	3.0	26
67	Impact of pre-enrolment medication use on clinical outcomes in SUMMIT. ERJ Open Research, 2019, 5, 00203-2018.	2.6	4
68	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. European Respiratory Journal, 2019, 53, 1900164.	6.7	1,223
69	External Validation and Recalculation of the CODEX Index in COPD Patients. A 3CIAplus Cohort Study. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2019, 16, 8-17.	1.6	7
70	Regional differences in rate of FEV1 decline in COPD: lessons from SUMMIT. European Respiratory Journal, 2019, 53, 1900278.	6.7	2
71	ValidaciÃ³n pronÃ³stica segÃºn los criterios de la GesEPOC 2017. Archivos De Bronconeumologia, 2019, 55, 409-413.	0.8	18
72	The Prevalence of Obstructive Lung Disease in a Lung Cancer Screening Cohort: Analysis of the National Lung Screening Trialâ€"American College of Radiology Image Network Cohort. Annals of the American Thoracic Society, 2019, 16, 641-644.	3.2	4

#	Article	IF	Citations
73	Chronic Obstructive Pulmonary Disease Biomarkers and Their Interpretation. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1195-1204.	5.6	94
74	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	3.2	11
75	Using the Peripheral Blood Eosinophil Count to Manage Patients with Chronic Obstructive Pulmonary Disease. Annals of the American Thoracic Society, 2019, 16, 301-303.	3.2	6
76	Inhalation Technique Errors with Metered-Dose Inhalers Among Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 267-280.	0.7	31
77	Exacerbations, Health Resource Utilization, and Costs Among Medicare Beneficiaries with Chronic Obstructive Pulmonary Disease Treated with Nebulized Arformoterol Following a Respiratory Event. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2019, 6, 297-307.	0.7	0
78	Î²-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of SUMMIT. Annals of the American Thoracic Society, 2018, 15, 608-614.	3.2	22
79	COPD as an endothelial disorder: endothelial injury linking lesions in the lungs and other organs? (2017 Grover Conference Series). Pulmonary Circulation, 2018, 8, 1-18.	1.7	90
80	Tabaquismo en pacientes con EPOC, Â¿un nuevo fenotipo clÃ¬nico?. Archivos De Bronconeumologia, 2018, 54, 249-250.	0.8	6
81	COPD: time to improve its taxonomy?. ERJ Open Research, 2018, 4, 00132-2017.	2.6	84
82	Exacerbations of Chronic Obstructive Pulmonary Disease and Cardiac Events. A Post Hoc Cohort Analysis from the SUMMIT Randomized Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 51-57.	5.6	192
83	At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1540-1551.	5.6	185
84	Long-Acting Î²-Agonist/Inhaled Corticosteroid in Patients with Chronic Obstructive Pulmonary Disease with Cardiovascular Disease or Risk: A Factorial Analysis of the SUMMIT Clinical Trial. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1641-1644.	5.6	4
85	Emphysema and extrapulmonary tissue loss in COPD: a multi-organ loss of tissue phenotype. European Respiratory Journal, 2018, 51, 1702146.	6.7	60
86	Cigarette smoking and response to inhaled corticosteroids in COPD. European Respiratory Journal, 2018, 51, 1701393.	6.7	27
87	A Historical Perspective of Pulmonary Rehabilitation. , 2018, , 3-18.		1
88	Large-scale external validation and comparison of prognostic models: an application to chronic obstructive pulmonary disease. BMC Medicine, 2018, 16, 33.	5.5	21
89	Shorter telomeres in non-smoking patients with airflow limitation. Respiratory Medicine, 2018, 138, 123-128.	2.9	6
90	Reply to Voelkel: Cigarette Smoke Is an Endothelial Cell Toxin. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 274-275.	5.6	1

#	Article	IF	Citations
91	Deterioration of Limb Muscle Function during Acute Exacerbation of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 433-449.	5.6	64
92	Comparison of the 2017 and 2015 Global Initiative for Chronic Obstructive Lung Disease Reports. Impact on Grouping and Outcomes. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 463-469.	5.6	63
93	Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. International Journal of COPD, 2018, Volume 13, 3971-3981.	2.3	56
94	Functional Studies of Single-Nucleotide Polymorphisms Suggest Heterogeneity in Chronic Obstructive Pulmonary Disease due to Susceptibility of Different Cell Types. Annals of the American Thoracic Society, 2018, 15, S285-S285.	3.2	1
95	Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFTÂ® trial. Respiratory Research, 2018, 19, 196.	3.6	19
96	Failure of Low-Dose Theophylline to Prevent Exacerbations in Patients With COPD. JAMA - Journal of the American Medical Association, 2018, 320, 1541.	7.4	0
97	Inhaled corticosteroids in COPD: friend or foe?. European Respiratory Journal, 2018, 52, 1801219.	6.7	166
98	The Challenge of Controlling the COPD Epidemic: Unmet Needs. American Journal of Medicine, 2018, 131, 1-6.	1.5	33
99	Prevalence of paradoxical bronchoconstriction after inhaled albuterol. Respiratory Medicine, 2018, 141, 100-102.	2.9	5
100	Targeting dyspnoea in patients with very severe COPD: Practical precision medicine. Respirology, 2018, 23, 1086-1087.	2.3	1
101	Improving Our Aim: Targeting Therapy with Roflumilast in Patients with Severe and Very Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1242-1244.	5.6	2
102	The effect of emphysema on readmission and survival among smokers with heart failure. PLoS ONE, 2018, 13, e0201376.	2.5	5
103	Precision medicine in COPD exacerbations. Lancet Respiratory Medicine,the, 2018, 6, 657-659.	10.7	23
104	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011.	5.6	111
105	The Course of Lung Function in Middle-aged Heavy Smokers: Incidence and Time to Early Onset of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1449-1451.	5.6	20
106	Pharmacological Therapy of COPD. Chest, 2018, 154, 1404-1415.	0.8	19
107	Supplementation with QterÂ® and Creatine improves functional performance in COPD patients on long term oxygen therapy. Respiratory Medicine, 2018, 142, 86-93.	2.9	28
108	Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive PulmonaryÂDisease. Journal of the American College of Cardiology, 2018, 72, 1126-1137.	2.8	48

#	Article	IF	Citations
109	Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial. European Heart Journal, 2018, 39, 3128-3134.	2.2	30
110	Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging: Evidence from the EpiChron Cohort. PLoS ONE, 2018, 13, e0193143.	2.5	70
111	Pulmonary arterial enlargement predicts long-term survival in COPD patients. PLoS ONE, 2018, 13, e0195640.	2.5	13
112	Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 47-55.	5.6	46
113	Chronic Obstructive Pulmonary Disease in Hispanics. A 9-Year Update. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 15-21.	5.6	14
114	Network analysis of autopsy diagnoses: Insights into the â€œcause of deathâ€•from unbiased disease clustering. Journal of Pathology Informatics, 2018, 9, 35.	1.7	1
115	Â¿Es realmente la enfermedad pulmonar obstructiva crÃ³nica una enfermedad progresiva?. Archivos De Bronconeumologia, 2017, 53, 362-363.	0.8	6
116	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601.	2.3	299
117	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal, 2017, 49, 1700214.	6.7	536
118	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	5.6	2,393
119	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.8	173
120	Different dyspnoea perception in COPD patients with frequent and infrequent exacerbations. Thorax, 2017, 72, 117-121.	5.6	53
121	Reply: Controlled Clinical Trials and Real-Life Experience with Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 797-797.	5.6	0
122	Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart, 2017, 103, 1536-1542.	2.9	41
123	Effect of a single exacerbation on decline in lung function in COPD. Respiratory Medicine, 2017, 128, 85-91.	2.9	53
124	Informe 2017 de la Iniciativa Global para el DiagnÃ³stico, Tratamiento y PrevenciÃ³n de la Enfermedad Pulmonar Obstructiva CrÃ³nica: Resumen Ejecutivo de GOLD. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.8	312
125	Telomere length, COPD and emphysema as risk factors for lung cancer. European Respiratory Journal, 2017, 49, 1601521.	6.7	19
126	Dissecting COPD exacerbations: time to rethink our definition. European Respiratory Journal, 2017, 50, 1701432.	6.7	16

#	Article	IF	Citations
127	A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034.	6.7	53
128	What does endotyping mean for treatment in chronic obstructive pulmonary disease?. Lancet, The, 2017, 390, 980-987.	13.7	78
129	Expert Statement on the Single-Agent Use of Inhaled Bronchodilator in the Treatment of Stable Mild-Moderate Chronic Obstructive Pulmonary Disease. Archivos De Bronconeumologia, 2017, 53, 574-582.	0.8	0
130	Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. Archivos De Bronconeumologia, 2017, 53, 415-416.	0.8	3
131	Is the Blood Eosinophil Count a Useful Biomarker in COPD? The devil is in the Details!. Archivos De Bronconeumologia, 2017, 53, 415-416.	0.8	1
132	Documento de expertos del uso de broncodilatadores inhalados en monoterapia en el tratamiento de la EPOC estable leve-moderada. Archivos De Bronconeumologia, 2017, 53, 574-582.	0.8	2
133	Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD patients with moderate airflow limitation: The SUMMIT trial. Respiratory Medicine, 2017, 131, 27-34.	2.9	29
134	Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. European Respiratory Journal, 2017, 50, 1701162.	6.7	122
135	Telomere shortening and accelerated aging in COPD: findings from the BODE cohort. Respiratory Research, 2017, 18, 59.	3.6	46
136	Clinical Features of Smokers With Radiological Emphysema But Without Airway Limitation. Chest, 2017, 151, 358-365.	0.8	29
137	Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 881-888.	5.6	49
138	Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 622-629.	5.6	94
139	Natural history of COPD: gaps and opportunities. ERJ Open Research, 2017, 3, 00117-2017.	2.6	40
140	Prospective comparison of non-invasive risk markers of major cardiovascular events in COPD patients. Respiratory Research, 2017, 18, 175.	3.6	11
141	Rapid decline in lung function in healthy adults predicts incident excess urinary albumin excretion later in life. BMJ Open Respiratory Research, 2017, 4, e000194.	3.0	1
142	Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study. International Journal of COPD, 2017, Volume 12, 2189-2196.	2.3	43
143	Impact and prevention of severe exacerbations of COPD: a review of the evidence. International Journal of COPD, 2017, Volume 12, 2891-2908.	2.3	162
144	The EASI model: A first integrative computational approximation to the natural history of COPD. PLoS ONE, 2017, 12, e0185502.	2.5	4

#	Article	IF	Citations
145	Agreement between a simple dyspnea-guided treatment algorithm for stable COPD and the GOLD guidelines: a pilot study. International Journal of COPD, 2016, 11, 1217.	2.3	11
146	Is COPD a Progressive Disease? A Long Term Bode Cohort Observation. PLoS ONE, 2016, 11, e0151856.	2.5	10
147	Identification of COPD Patients at High Risk for Lung Cancer Mortality Using the COPD-LUCSS-DLCO. Chest, 2016, 149, 936-942.	0.8	55
148	Prognostic assessment in COPD without lung function: the B-AE-D indices. European Respiratory Journal, 2016, 47, 1635-1644.	6.7	37
149	Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet, The, 2016, 387, 1817-1826.	13.7	378
150	Differences in Health-Related Quality of Life Between New Mexican Hispanic and Non-Hispanic White Smokers. Chest, 2016, 150, 869-876.	0.8	8
151	Determinants of exercise-induced oxygen desaturation including pulmonary emphysema in COPD: Results from the ECLIPSE study. Respiratory Medicine, 2016, 119, 87-95.	2.9	29
152	DNA methylation profiling in human lung tissue identifies genes associated with COPD. Epigenetics, 2016, 11, 730-739.	2.7	73
153	Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study. Respiratory Research, 2016, 17, 147.	3.6	36
154	What is asthmaâ"COPD overlap syndrome? Towards a consensus definition from a round table discussion. European Respiratory Journal, 2016, 48, 664-673.	6.7	287
155	The BODECOST Index (BCI): a composite index for assessing the impact of COPD in real life. Multidisciplinary Respiratory Medicine, 2016, 11, 10.	1.5	2
156	Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFTÂ® trial. Respiratory Research, 2016, 17, 48.	3.6	6
157	The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 1483-1493.	5.6	83
158	Club Cell Protein 16 (CC16) Augmentation: A Potential Disease-modifying Approach for Chronic Obstructive Pulmonary Disease (COPD). Expert Opinion on Therapeutic Targets, 2016, 20, 869-883.	3.4	60
159	Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA - Journal of the American Medical Association, 2016, 315, 672.	7.4	333
160	Simplificando las guÃas: los 10 mandamientos de la EPOC. Archivos De Bronconeumologia, 2016, 52, 179-180.	0.8	11
161	Handgrip weakness and mortality risk in COPD: a multicentre analysis. Thorax, 2016, 71, 86-87.	5.6	53
162	Exacerbations, health services utilization, and costs in commercially-insured COPD patients treated with nebulized long-actingÎ²2-agonists. Journal of Medical Economics, 2016, 19, 11-20.	2.1	6

#	Article	IF	Citations
163	Identification of Barriers to Influenza Vaccination in Patients with Chronic Obstructive Pulmonary Disease: Analysis of the 2012 Behavioral Risk Factors Surveillance Survey. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2016, 3, 620-627.	0.7	15
164	Maximal Oxygen Uptakeâ€"Risk Predictor of NSCLC Resection in Patients With Comorbid Emphysema: Lessons From NETT. Seminars in Thoracic and Cardiovascular Surgery, 2015, 27, 225-231.	0.6	8
165	Mortality and drug therapy in patients with chronic obstructive pulmonary disease: a network meta-analysis. BMC Pulmonary Medicine, 2015, 15, 145.	2.0	14
166	Chronic obstructive pulmonary disease. Nature Reviews Disease Primers, 2015, 1, 15076.	30.5	444
167	COPD (confusion over proper diagnosis) in the zone of maximum uncertainty. European Respiratory Journal, 2015, 46, 1525-1526.	6.7	4
168	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. International Journal of COPD, 2015, 10, 549.	2.3	26
169	B Cellâ€"Activating Factor. An Orchestrator of Lymphoid Follicles in Severe Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 695-705.	5.6	89
170	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	7.1	72
171	Prevention of Acute Exacerbations of COPD. Chest, 2015, 147, 894-942.	0.8	230
172	We must join forces in the battle against COPD. European Respiratory Journal, 2015, 46, 1528-1528.	6.7	0
173	Protective role for club cell secretory protein-16 (CC16) in the development of COPD. European Respiratory Journal, 2015, 45, 1544-1556.	6.7	115
174	Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. Annals of the American Thoracic Society, 2015, 12, 303-312.	3.2	126
175	A Novel Nonhuman Primate Model of Cigarette Smokeâ€"Induced Airway Disease. American Journal of Pathology, 2015, 185, 741-755.	3.8	31
176	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respiratory Medicine,the, 2015, 3, 443-450.	10.7	125
177	Clinical and prognostic heterogeneity of C and D GOLD groups. European Respiratory Journal, 2015, 46, 250-254.	6.7	11
178	Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2015, 373, 111-122.	27.0	974
179	COPD comorbidities network. European Respiratory Journal, 2015, 46, 640-650.	6.7	145
180	Recommendations for the early diagnosis of COPD: the AIMAR view. Multidisciplinary Respiratory Medicine, 2015, 10, 6.	1.5	4

#	Article	IF	Citations
181	Executive Summary. Chest, 2015, 147, 883-893.	0.8	51
182	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 191, e4-e27.	5.6	166
183	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Journal, 2015, 45, 879-905.	6.7	138
184	Low plasma CC16 levels in smokers are associated with a higher risk for chronic bronchitis. European Respiratory Journal, 2015, 46, 1501-1503.	6.7	19
185	Prognostic value of variables derived from the six-minute walk test in patients with COPD: Results from the ECLIPSE study. Respiratory Medicine, 2015, 109, 1138-1146.	2.9	77
186	Continuous fat-free mass decline in COPD: fact or fiction?. European Respiratory Journal, 2015, 46, 1496-1498.	6.7	12
187	Effect of Tiotropium on Outcomes in Patients With COPD, Categorized Using the New GOLD Grading System: Results of the UPLIFTÂ® Randomized Controlled Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2015, 2, 236-251.	0.7	3
188	Disease progression in young patients with COPD: rethinking the Fletcher and Peto model. European Respiratory Journal, 2014, 44, 324-331.	6.7	57
189	Sexually-dimorphic targeting of functionally-related genes in COPD. BMC Systems Biology, 2014, 8, 118.	3.0	47
190	Longitudinal assessment in COPD patients: multidimensional variability and outcomes. European Respiratory Journal, 2014, 43, 745-753.	6.7	37
191	Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. Thorax, 2014, 69, 718-723.	5.6	151
192	Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax, 2014, 69, 799-804.	5.6	82
193	Airflow reversibility and long-term outcomes in patients with COPD without comorbidities. Respiratory Medicine, 2014, 108, 1180-1188.	2.9	21
194	Should We View Chronic Obstructive Pulmonary Disease Differently after ECLIPSE?. A Clinical Perspective from the Study Team. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 1022-1030.	5.6	130
195	Assessment of five different guideline indication criteria for spirometry, including modified GOLD criteria, in order to detect COPD: data from 5,315 subjects in the PLATINO study. Npj Primary Care Respiratory Medicine, 2014, 24, 14075.	2.6	11
196	Native American Ancestry, Lung Function, and COPD in Costa Ricans. Chest, 2014, 145, 704-710.	0.8	23
197	Rebuttal From Dr Celli. Chest, 2014, 145, 1195-1196.	0.8	0
198	Counterpoint: Should Storefront Clinics Provide Case Finding and Chronic Care for COPD? No. Chest, 2014, 145, 1193-1194.	0.8	3

#	Article	IF	Citations
199	Rapid Lung Function Decline in Smokers Is a Risk Factor for COPD and Is Attenuated by Angiotensin-Converting Enzyme Inhibitor Use. Chest, 2014, 145, 695-703.	0.8	60
200	Obstructive Lung Disease in Mexican Americans and Non-Hispanic Whites. Chest, 2014, 145, 282-289.	0.8	16
201	Once-Daily Umeclidinium/Vilanterol 125/25 Î¼g Therapy in COPD. Chest, 2014, 145, 981-991.	0.8	142
202	Finding the Best Thresholds of FEV1 and Dyspnea to Predict 5-Year Survival in COPD Patients: The COCOMICS Study. PLoS ONE, 2014, 9, e89866.	2.5	43
203	Comorbidity Distribution, Clinical Expression and Survival in COPD Patients with Different Body Mass Index. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2014, 1, 229-238.	0.7	38
204	Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations: A Post-Hoc Analysis from the 4-Year UPLIFTÂ® Trial. Chronic Obstructive Pulmonary Diseases (Miami, Fla) Tj ETQq0 0 0 rgBT /Overlock 10	0.7	6
205	The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2013, 7, 57-64.	2.5	26
206	The club cell and its protein, CC16: time to shine. Lancet Respiratory Medicine,the, 2013, 1, 757-759.	10.7	9
207	Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respiratory Medicine, 2013, 107, 1376-1384.	2.9	328
208	The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study protocol. European Respiratory Journal, 2013, 41, 1017-1022.	6.7	81
209	The COPD Biomarker Qualification Consortium (CBQC). COPD: Journal of Chronic Obstructive Pulmonary Disease, 2013, 10, 367-377.	1.6	67
210	Exploring the impact of screening with low-dose CT on lung cancer mortality in mild to moderate COPD patients: A pilot study. Respiratory Medicine, 2013, 107, 702-707.	2.9	50
211	Annual rates of change in pre- vs. post-bronchodilator FEV1 and FVC over 4 years in moderate to very severe COPD. Respiratory Medicine, 2013, 107, 1904-1911.	2.9	18
212	The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study. Lancet Respiratory Medicine,the, 2013, 1, 129-136.	10.7	224
213	Six-Minute-Walk Test in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 382-386.	5.6	257
214	Distribution and Prognostic Validity of the New Global Initiative for Chronic Obstructive Lung Disease Grading Classification. Chest, 2013, 143, 694-702.	0.8	120
215	Multicomponent indices to predict survival in COPD: the COCOMICS study. European Respiratory Journal, 2013, 42, 323-332.	6.7	93
216	Changes in Body Composition in Patients with Chronic Obstructive Pulmonary Disease: Do They Influence Patient-Related Outcomes?. Annals of Nutrition and Metabolism, 2013, 63, 239-247.	1.9	46

#	Article	IF	Citations
217	Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. European Respiratory Journal, 2013, 42, 636-646.	6.7	164
218	Treadmill Endurance During 2-Year Treatment With Tiotropium in Patients With COPD. Chest, 2013, 144, 490-497.	0.8	42
219	Characterizing Functional Lung Heterogeneity in COPD Using Reference Equations for CT Scan-Measured Lobar Volumes. Chest, 2013, 143, 1607-1617.	0.8	12
220	Epicardial Adipose Tissue in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE, 2013, 8, e65593.	2.5	20
221	Comparison of arterial and venous blood biomarker levels in chronic obstructive pulmonary disease. F1000Research, 2013, 2, 114.	1.6	4
222	Systemic Biomarkers in the Evaluation and Management of COPD Patients: Are We Getting Closer to Clinical Application?. Current Drug Targets, 2013, 14, 177-191.	2.1	26
223	Chronic Obstructive Pulmonary Disease and Lung Cancer. Proceedings of the American Thoracic Society, 2012, 9, 74-79.	3.5	32
224	The Expanding Role of Biomarkers in the Assessment of Smoking-Related Parenchymal Lung Diseases. Chest, 2012, 142, 1027-1034.	0.8	35
225	Genome-Wide Association Analysis of Blood Biomarkers in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1238-1247.	5.6	117
226	Preface. Medical Clinics of North America, 2012, 96, xi-xii.	2.5	0
227	Predicting Outcomes from 6-Minute Walk Distance in Chronic Obstructive Pulmonary Disease. Journal of the American Medical Directors Association, 2012, 13, 291-297.	2.5	193
228	Treatment of the Stable Patient with Chronic Obstructive Pulmonary Disease. , 2012, , 553-561.		0
229	Inflammatory Biomarkers Improve Clinical Prediction of Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1065-1072.	5.6	353
230	Longitudinal inspiratory capacity changes in chronic obstructive pulmonary disease. Respiratory Research, 2012, 13, 66.	3.6	20
231	Comorbidities and Risk of Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 155-161.	5.6	946
232	Health effects of the Federal Bureau of Prisons tobacco ban. BMC Pulmonary Medicine, 2012, 12, 64.	2.0	6
233	Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype. PLoS ONE, 2012, 7, e37483.	2.5	633
234	Six-Minute Walking Distance in Women with COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 300-305.	1.6	10

#	Article	IF	Citations
235	Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD. Respiratory Medicine, 2011, 105, 580-587.	2.9	96
236	Prognostic assessment in COPD: Health related quality of life and the BODE index. Respiratory Medicine, 2011, 105, 916-921.	2.9	53
237	Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD. Respiratory Medicine, 2011, 105, 1176-1188.	2.9	27
238	Premature discontinuation during the UPLIFT study. Respiratory Medicine, 2011, 105, 1523-1530.	2.9	20
239	Gender Differences in Plasma Biomarker Levels in a Cohort of COPD Patients: A Pilot Study. PLoS ONE, 2011, 6, e16021.	2.5	44
240	Efficacy of tiotropium in COPD patients from Asia: A subgroup analysis from the UPLIFT trial. Respirology, 2011, 16, 825-835.	2.3	43
241	Bias due to withdrawal in longâ€term randomised trials in COPD: Evidence from the TORCH study. Clinical Respiratory Journal, 2011, 5, 44-49.	1.6	78
242	Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial. Respiratory Research, 2011, 12, 129.	3.6	25
243	Health status in the TORCH study of COPD: treatment efficacy and other determinants of change. Respiratory Research, 2011, 12, 71.	3.6	60
244	Sex Differences in Mortality and Clinical Expressions of Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 317-322.	5.6	157
245	The EXACT-Pro: Measuring Exacerbations of COPD. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 287-288.	5.6	15
246	Genome-Wide Association Analysis of Body Mass in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2011, 45, 304-310.	2.9	50
247	The Progression of Chronic Obstructive Pulmonary Disease Is Heterogeneous. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1015-1021.	5.6	197
248	Bronchodilator Reversibility in COPD. Chest, 2011, 140, 1055-1063.	0.8	80
249	Addressing the Complexity of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1129-1137.	5.6	166
250	Changes in Forced Expiratory Volume in 1 Second over Time in COPD. New England Journal of Medicine, 2011, 365, 1184-1192.	27.0	811
251	Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 913-919.	5.6	266
252	Opportunities and Challenges in the Genetics of COPD 2010: An International COPD Genetics Conference Report. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2011, 8, 121-135.	1.6	43

#	Article	IF	Citations
253	Management Guidelines for Chronic Obstructive Pulmonary Disease. , 2011, , 81-98.		0
254	Point: Should We Abandon FEV 1 /FVC <0.70 To Detect Airway Obstruction? No. Chest, 2010, 138, 1037-1040.	0.8	46
255	Lung Volume Reduction Therapies for Advanced Emphysema. Chest, 2010, 138, 407-417.	0.8	53
256	Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 2010, 11, 122.	3.6	952
257	Outcomes in Patients with Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 325-331.	5.6	589
258	Microalbuminuria and Hypoxemia in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 1004-1010.	5.6	72
259	Determinants of poor 6-min walking distance in patients with COPD: The ECLIPSE cohort. Respiratory Medicine, 2010, 104, 849-857.	2.9	171
260	Predictors of mortality in COPD. Respiratory Medicine, 2010, 104, 773-779.	2.9	145
261	Effect of tiotropium in men and women with COPD: Results of the 4-year UPLIFTÂ® trial. Respiratory Medicine, 2010, 104, 1495-1504.	2.9	68
262	Chronic Obstructive Pulmonary Disease Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 598-604.	5.6	898
263	Cardiovascular events in patients with COPD: TORCH Study results. Thorax, 2010, 65, 719-725.	5.6	177
264	Prevalence and Progression of Osteoporosis in Patients With COPD. Chest, 2009, 136, 1456-1465.	0.8	240
265	Effect of Pharmacotherapy on Rate of Decline of FEV1in the TORCH Study. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 426-427.	5.6	0
266	Mortality in the 4-Year Trial of Tiotropium (UPLIFT) in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 948-955.	5.6	252
267	Prediction of risk of COPD exacerbations by the BODE index. Respiratory Medicine, 2009, 103, 373-378.	2.9	116
268	Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respiratory Research, 2009, 10, 59.	3.6	287
269	Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet, The, 2009, 374, 1171-1178.	13.7	430
270	Prognostic assessment of patients with COPD. Lancet, The, 2009, 374, 1885.	13.7	11

#	Article	IF	Citations
271	Does Pharmacotherapy Reduce the Rate of Decline of Lung Function in COPD?. American Journal of Respiratory and Critical Care Medicine, 2009, 179, 171-172.	5.6	2
272	Women with chronic obstructive pulmonary disease: an emerging phenotype of the disease. Therapy: Open Access in Clinical Medicine, 2009, 6, 821-830.	0.2	3
273	Novel concepts in the pharmacotherapy of chronic obstructive pulmonary disease. Pneumonologia I Alergologia Polska, 2009, 77, 82-90.	0.6	0
274	A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 1543-1554.	27.0	1,969
275	Time to desaturation in the 6-min walking distance test predicts 24-hour oximetry in COPD patients with a PO2 between 60 and 70mmHg. Respiratory Medicine, 2008, 102, 1026-1032.	2.9	37
276	Predictors of Survival in COPD: More than Just the FEV1. Respiratory Medicine, 2008, 102, S27-S35.	2.9	117
277	Distance and Oxygen Desaturation During the 6-min Walk Test as Predictors of Long-term Mortality in Patients With COPD. Chest, 2008, 134, 746-752.	0.8	254
278	Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 332-338.	5.6	692
279	Longitudinal Change in the BODE Index Predicts Mortality in Severe Emphysema. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 491-499.	5.6	114
280	Update on the Management of COPD. Chest, 2008, 133, 1451-1462.	0.8	103
281	C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD. Chest, 2008, 133, 1336-1343.	0.8	127
282	Lung Volume Reduction in Patients with COPD: Physiological and Clinical Implications. Current Respiratory Medicine Reviews, 2008, 4, 312-320.	0.2	0
283	Biological Lung Volume Reduction. Chest, 2007, 131, 1108-1113.	0.8	125
284	Differences in Cardiopulmonary Exercise Test Results by American Thoracic Society/European Respiratory Society-Global Initiative for Chronic Obstructive Lung Disease Stage Categories and Gender. Chest, 2007, 132, 1204-1211.	0.8	50
285	Impact of COPD Exacerbations on Patient-Centered Outcomes. Chest, 2007, 131, 696-704.	0.8	219
286	Systemic Cytokines, Clinical and Physiological Changes in Patients Hospitalized for Exacerbation of COPD. Chest, 2007, 131, 37-43.	0.8	117
287	The 6-Min Walk Distance, Peak Oxygen Uptake, and Mortality in COPD. Chest, 2007, 132, 1778-1785.	0.8	205
288	Salmeterol and Fluticasone Propionate and Survival in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2007, 356, 775-789.	27.0	2,963

#	Article	IF	Citations
289	Predictors of Mortality in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2007, 28, 515-524.	2.1	31
290	Profiling serum biomarkers in patients with COPD: associations with clinical parameters. Thorax, 2007, 62, 595-601.	5.6	170
291	Gender and respiratory factors associated with dyspnea in chronic obstructive pulmonary disease. Respiratory Research, 2007, 8, 18.	3.6	61
292	COPD heterogeneity: gender differences in the multidimensional BODE index. International Journal of COPD, 2007, 2, 151-5.	2.3	5
293	Chronic Obstructive Pulmonary Disease: From Unjustified Nihilism to Evidence-based Optimism. Proceedings of the American Thoracic Society, 2006, 3, 58-65.	3.5	47
294	Gender associated differences in determinants of quality of life in patients with COPD: a case series study. Health and Quality of Life Outcomes, 2006, 4, 72.	2.4	98
295	American Thoracic Society/European Respiratory Society Statement on Pulmonary Rehabilitation. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1390-1413.	5.6	1,644
296	Markers of disease severity in chronic obstructive pulmonary disease. Pulmonary Pharmacology and Therapeutics, 2006, 19, 189-199.	2.6	127
297	Change in the BODE Index Reflects Disease Modification in COPD. Chest, 2006, 129, 835-836.	0.8	27
298	Effect of Fluticasone Propionate/Salmeterol on Lung Hyperinflation and Exercise Endurance in COPD. Chest, 2006, 130, 647-656.	0.8	205
299	Predicting Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 1298-1299.	5.6	8
300	Roger S. Mitchell Lecture. Chronic Obstructive Pulmonary Disease Phenotypes and Their Clinical Relevance. Proceedings of the American Thoracic Society, 2006, 3, 461-465.	3.5	54
301	Use of Proteomic Patterns of Serum Biomarkers in Patients with Chronic Obstructive Pulmonary Disease: Correlation with Clinical Parameters. Proceedings of the American Thoracic Society, 2006, 3, 465-466.	3.5	28
302	Discrepancy in the use of confirmatory tests in patients hospitalized with the diagnosis of chronic obstructive pulmonary disease or congestive heart failure. Respiratory Care, 2006, 51, 1120-4.	1.6	66
303	Gender and COPD in Patients Attending a Pulmonary Clinic. Chest, 2005, 128, 2012-2016.	0.8	214
304	New treatment strategies for COPD. Postgraduate Medicine, 2005, 117, 27-34.	2.0	4
305	Inspiratory-to-Total Lung Capacity Ratio Predicts Mortality in Patients with Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 591-597.	5.6	514
306	Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respiratory Medicine, 2005, 99, 1546-1554.	2.9	59

#	Article	IF	Citations
307	Future perspectives in COPD. Respiratory Medicine, 2005, 99, S41-S48.	2.9	17
308	Airway obstruction in never smokers: Results from the Third National Health and Nutrition Examination Survey. American Journal of Medicine, 2005, 118, 1364-1372.	1.5	156
309	Gene Expression Profiling of Human Lung Tissue from Smokers with Severe Emphysema. American Journal of Respiratory Cell and Molecular Biology, 2004, 31, 601-610.	2.9	159
310	Clinical Trial Design Considerations in Assessing Longâ€Term Functional Impacts of Tiotropium in COPD: The Uplift Trial. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2004, 1, 303-312.	1.6	152
311	The Body-Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2004, 350, 1005-1012.	27.0	3,409
312	A comparison of 5-day courses of dirithromycin and azithromycin in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clinical Therapeutics, 2003, 25, 542-557.	2.5	31
313	A 62-Year-Old Woman With Chronic Obstructive Pulmonary Disease. JAMA - Journal of the American Medical Association, 2003, 290, 2721.	7.4	1
314	Improvement in Resting Inspiratory Capacity and Hyperinflation With Tiotropium in COPD Patients With Increased Static Lung Volumes *. Chest, 2003, 124, 1743-1748.	0.8	278
315	Pulmonary rehabilitation. Israel Medical Association Journal, 2003, 5, 443-8.	0.1	1
316	Power of Outcome Measurements to Detect Clinically Significant Changes in Pulmonary Rehabilitation of Patients With COPD. Chest, 2002, 121, 1092-1098.	0.8	214
317	Cough and Phlegm Are Important Predictors of Health Status in Smokers Without COPD. Chest, 2002, 121, 1427-1433.	0.8	30
318	Long-term Controlled Trial of Nocturnal Nasal Positive Pressure Ventilation in Patients With Severe COPD. Chest, 2000, 118, 1582-1590.	0.8	312
319	Ventilatory Drive at Rest and Perception of Exertional Dyspnea in Severe COPD. Chest, 1999, 115, 1293-1300.	0.8	59
320	Pulmonary rehabilitation for COPD. Postgraduate Medicine, 1998, 103, 159-176.	2.0	9
321	Lung Reduction Surgery in Severe COPD Decreases Central Drive and Ventilatory Response to CO2. Chest, 1997, 112, 902-906.	0.8	25
322	Upper Airway Diseases. , 0, , 513-527.		0
323	The use of multidimensional indices. , 0, , 143-160.		1